Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction.

Published

Journal Article (Review)

PURPOSE OF REVIEW: The use of biomarkers in heart failure (HF) is a rapidly changing field. The purpose of this review is to assess the current evidence of the use of biomarkers for risk stratification in patients with HF with preserved ejection fraction (HFpEF). RECENT FINDINGS: Despite differences in pathophysiology between HF with reduced ejection fraction and HFpEF, traditional HF biomarkers such as brain natriuretic peptide and troponin retain prognostic value in most HFpEF-specific populations. Biomarkers of key pathophysiologic components of HFpEF, such as myocardial fibrosis, remodeling, and systemic inflammation are also valuable prognostic markers. Further investigation into HF biomarkers may identify significant therapeutic targets for the treatment of HFpEF.

Full Text

Duke Authors

Cited Authors

  • Cypen, J; Ahmad, T; Testani, JM; DeVore, AD

Published Date

  • October 2017

Published In

Volume / Issue

  • 14 / 5

Start / End Page

  • 434 - 443

PubMed ID

  • 28803400

Pubmed Central ID

  • 28803400

Electronic International Standard Serial Number (EISSN)

  • 1546-9549

Digital Object Identifier (DOI)

  • 10.1007/s11897-017-0358-4

Language

  • eng

Conference Location

  • United States